<DOC>
	<DOCNO>NCT02244541</DOCNO>
	<brief_summary>The primary objective Phase 2a study evaluate maximal tolerate dose ANAVEX2-73 patient AD repeated-dose administration scheme , secondary objective explore relationship dose regimen pharmacodynamics efficacy outcomes evaluate bioavailability oral form use explore relationship ANAVEX2-73 add-on therapy AD standard care .</brief_summary>
	<brief_title>Phase 2a Dose Finding , PK/PD 12 Month Exploratory Efficacy Study ANAVEX2-73 Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>This Phase 2a study consist two part , PART A PART B . The first part ( PART A ) simple randomise , open-label , 2-period , cross-over , adaptive design study last participant 36 day . The second part ( PART B ) open-label extension additional period 52 week , establish long drug effect participant wish continue oral daily dose . The complete timeline study include screen assessment within 28 day prior simple randomisation initiation study . The first administration study medication occur baseline screening procedure pass ( baseline define pre-dosing period timeframe day -28 day -1 ) . No study procedures undertaken current inform consent form sign participant respective carer responsible person . The design first part ( PART A ) study involve two period , two administration route two dose level : In one period intravenous ( iv ) form give period oral dose give . The first period involve 12 administration ( either oral iv ) second period involve 11 administration ( either oral iv ) . The first administration first period intend full pharmacokinetic ( PK ) screen first 48 hour ( Day 1 Day 3 ) . After , 11 daily administration complete first period ( Day 3 Day 13 ) . After wash-out period 11 day , second period study start , involve 11 daily administration . Therefore , first part ( PART A ) study schedule complete 36 day . The study design ask 32 participant , 16 male 16 female participant . All participant option go second part ( PART B ) study , extend open-label study explore cognitive effect drug another 52 week oral form exclusively administer . Safety tolerability constantly assess throughout study , start first dose study medication .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Main 1 . Diagnosis Probable AD accordance NINCDSADRDA criterion . 2 . A brain CT MRI scan perform within last 12 month day screen consistent clinical diagnosis probable AD . 3 . Age 55 85 year inclusive . 4 . MMSE score 1628 inclusive . 5 . Rosen Modified Hachinski Ischemic score &lt; =4 . 6 . Community dwell caregiver regular contact subject least 10 hour per week able oversee patient 's compliance study medication participate patient 's clinical assessment capable accompany participant clinic visit . 7 . Fluency English . 8 . Be able read , write , speak clearly cognitive test , eyesight hear sufficient enable completion cognitive test . 9 . Receiving stable dos medication treatment nonexcluded medical condition least 30 day prior screen . Main 1 . Dementia AD AIDS , CJD , LBD , CVD , Progressive Supranuclear Palsy , Multiple cerebral infarct , normal pressure hydrocephalus . 2 . Other neurodegenerative disease , include Parkinson 's disease Huntington 's disease , cerebral tumour . 3 . Current presence clinically significant major psychiatric disorder accord criterion DSMIV , symptom could affect participant 's ability complete study ) . HAMD score &gt; 12 . 4 . Current clinically significant systemic illness likely result deterioration patient 's condition affect patient 's safety study . 5 . Any criteria opinion Investigator cause participant qualify study .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>